Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yuuki, Kogure"'
Autor:
Daisuke Ueki, Shinya Suzuki, Takahiro Ohta, Akira Shinohara, Yasukata Ohashi, Daisuke Konuma, Yasuaki Ryushima, Ryoko Udagawa, Hironori Motoshige, Masahiro Ieoka, Akihiro Taji, Yuuki Kogure, Mikako Hiraike, Miyuki Uoi, Kazuhiko Ino, Toshikatsu Kawasaki, Masakazu Yamaguchi
Publikováno v:
Pharmacy, Vol 12, Iss 1, p 1 (2023)
Although prescription review is an important role for pharmacists in anticancer drug therapy, there are no guidelines in Japan that specify what pharmacists should check for in chemotherapy regimens. This prospective multicenter survey aimed to inves
Externí odkaz:
https://doaj.org/article/affda06035f2417e91f2adfbc852a57e
Autor:
Masahiko Nakao, Yuuki Kogure, Yohei Kawasaki, Kenichi Suzuki, Keita Hirai, Kazuyuki Inoue, Makoto Nishio, H. Ayuhara, Daiki Tsuji, Mari Yokoi, Koji Takeda, Kunihiko Itoh, Toshihiro Hama, Toshinobu Hayashi, Kazuhiko Shibata
Publikováno v:
Supportive Care in Cancer.
Younger age and female sex have already been well-known risk factors for chemotherapy-induced nausea and vomiting (CINV), and 30–50% of cancer patients still suffer from CINV. Genetic polymorphisms are suggested to influence antiemetic treatment re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8df24baf30d77c435d4983ba4bc1a907
https://doi.org/10.1007/s00520-017-3974-3
https://doi.org/10.1007/s00520-017-3974-3
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 37(1)
Paclitaxel (PTX) is one of the most important breast cancer treatment drugs. However, severe hypersensitivity reactions such as decreases in blood pressure and impaired breathing occur with high frequency. For the prevention of such hypersensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e45cf5f6d2ec53fce6349fd11aaccf8e
https://pubmed.ncbi.nlm.nih.gov/20087041
https://pubmed.ncbi.nlm.nih.gov/20087041
Publikováno v:
Annals of Oncology. 25:v106
Background: Radioimmunotherapy of Yttrium-90 (90Y)-ibritumomab tixetan is less toxic and unique therapy. Ibritumomab tixetan is a 90Y-conjugated monoclonal antibody to CD20 for patients with B cell non-Hodgikins lymphoma. Patients and methods: We inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb7240f970647442aaa2ebb2e3a00e94
https://doi.org/10.1093/annonc/mdu436.140
https://doi.org/10.1093/annonc/mdu436.140